PLOS Medicine

Performance of serum apolipoprotein-A1 as a sentinel of Covid-19 --Manuscript Draft--

Manuscript Number:			
Full Title:	Performance of serum apolipoprotein-A1 as a sentinel of Covid-19		
Short Title:	Apolipoprotein-A1 decrease in Covid-19		
Article Type:	Research Article		
Section/Category:	Health Systems		
Corresponding Author:	Thierry Poynard Assistance Publique - Hopitaux de Paris Paris, FRANCE		
Corresponding Author Secondary Information:			
Corresponding Author's Institution:	Assistance Publique - Hopitaux de Paris		
Corresponding Author's Secondary Institution:			
First Author:	Thierry Poynard		
First Author Secondary Information:			
Order of Authors:	Thierry Poynard		
	Olivier Deckmyn		
	Marika Rudler		
	Valentina Peta		
	Yen Ngo		
	Mathieu Vautier		
	Sepideh Akhavan		
	Vincent Calvez		
	Clemence Franc		
	Jean Marie Castille		
	Fabienne Drane		
	Mehdi Sakka		
	Dominique Bonnefont-Rousselot		
	Jean Marc Lacorte		
	David Saadoun		
	Yves Allenbach		
	Olivier Benveniste		
	Frederique Gandjbakhch		
	Julien Mayaux		
	Olivier Lucidarme		
	Bruno Fautrel		
	Vlad Ratziu		
	Chantal Housset		
NOTE: This preprint reports new resear	ch that has not been certified by peer review and should not be used to guide clinical practice.		

	Dominique Thabut
	Patrice Cacoub
Order of Authors Secondary Information:	
Abstract:	During the 30 weeks of 2020 we observed in two large cohorts of patients at risk of liver fibrosis a highly significant decrease of serum apolipoprotein-A1, not observed in previous years. This decrease was highly correlated to and in parallel with the daily increase in confirmed Covid-19 cases, including the recovery period. Meaning Apolipoprotein-A1 could be used as a sentinel of the pandemic in existing routine surveillance of the general population.
Additional Information:	curve marios of the general population.
Question	Response
Financial Disclosure	European Grant EIT health ProCoP 20879
Enter a financial disclosure statement that describes the sources of funding for the work included in this submission. Review the submission guidelines for detailed requirements. View published research articles from PLOS Medicine for specific examples. This statement is required for submission and will appear in the published article if the submission is accepted. Please make sure it is accurate. Unfunded studies Enter: The author(s) received no specific funding for this work. Funded studies Enter a statement with the following details: Initials of the authors who received each award Grant numbers awarded to each author The full name of each funder URL of each funder website Did the sponsors or funders play any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript? NO - Include this sentence at the end of your statement: The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. YES - Specify the role(s) played.	Patrice Cacoub

* typeset

Competing Interests

Use the instructions below to enter a competing interest statement for this submission. On behalf of all authors, disclose any competing interests that could be perceived to bias this work—acknowledging all financial support and any other relevant financial or non-financial competing interests.

This statement will appear in the published article if the submission is accepted. Please make sure it is accurate. View published research articles from <u>PLOS Medicine</u> for specific examples.

NO authors have competing interests

Enter: The authors have declared that no competing interests exist.

Authors with competing interests

Enter competing interest details beginning with this statement:

I have read the journal's policy and the authors of this manuscript have the following competing interests: [insert competing interests here]

* typeset

I have read the journal's policy and the authors of this manuscript have the following competing interests:

Thierry Poynard is the inventor of FibroTest, founder of BioPredictive, the patents belong to the public organization Assistance Publique-Hôpitaux de Paris. Olivier Deckmyn, Valentina Peta, Yen Ngo, Jean Marie Castille, Fabienne Drane and Clemence Franc are full employees of BioPredictive. The other authors have nothing to declare.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.01.20186213; this version posted September 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

All rights reserved. No reuse allowed without permission.

Cover letter

Dear Editor

We submit to PlosMedicine an article entitled "Performance of serum apolipoprotein-A1 as a sentinel of Covid-19".

I share my professional life with apolipoprotein-A1 (ApoA1) since 1982, with a prospective cohort of 975 heavy French drinkers, followed by several other cohorts looking for fibrosis biomarkers.

In February 2020, serendipity scenario.

Our Hepatology department of Pitié-Salpêtrière, was transformed in a Covid-19 center and I rapidly observed in these severe patients a specific profile of Apo-A1 decrease and Haptoglobin increase, never observed before.

The night after, I realize that we have online more than 1 million of ApoA1 and Haptoglobin in the cohorts of patients followed by FibroTest for a risk of liver fibrosis. Therefore, we compared daily the ongoing year 2020 to previous years "Covid-Free". Indeed, there was a highly significant decrease in ApoA1 parallel (2 weeks before) to the confirmed Covid-19 cases.

The most original result was that this decrease started few weeks before the incidence of confirmed cases, suggesting that ApoA1 detected infected cases. Furthermore, the liver function biomarkers as well as the Haptoglobin did not change so early.



We observed the normalization of apolipoprotein-A1 in the sera of the French cohort in June, in parallel with the decrease of daily confirmed Covid-19 cases, as well as the plateau in the US cohort.

Apolipoprotein-A1 could be a very simple early marker of the Covid-19 pandemic, as suggested in two ongoing surveillance databases, in France and USA with high sensitivity and specificity. It can be done immediately and with low cost in routine surveillance already dosing apolipoprotein-A1, as well as in patients with a clinical suspicion of Covid-19 but with a negative virologic test.

We do think that this article will help clinicians immediately, in the phase of a possible second wave, and epidemiologists for estimating the prevalence of infected subjects in general population, using other surveillance cohorts. Furthermore, our results suggest a potential intestinal transmission without liver signals.

This manuscript has not been presented or is not submitted elsewhere. None of the material concerning the large surveillance databases and the prospective observational cohort has been published or is under consideration for publication elsewhere.

According to the context of the pandemic, for assessing the specificity we used controls previously published in large studies of liver diseases. This permitted to have a wide spectrum of false positive risk. These measurements have been all performed on fresh serum collected prospectively and analyzed in the biochemistry unit of Pitié-Salpêtrière Hospital, Paris, France, with the same biochemical methods as for the prospective Covid-19 cases.

The prospective observational study in Covid-19 patients was approved by CER-Sorbonne University IRB, N° 2020–CER-2020-14, with a signed informed consent. Clinical investigation was conducted according to the principles of the Declaration of Helsinki. All authors had access to the study data and reviewed and approved the final manuscript. The components of Fibrotest and Nash-FibroTest were measured in routine in all patients with a risk of liver disease in France. The different databases integrated were used on sera anonymously. All the retrospective database analyses previously published either non-interventional study, without supplementary blood sample, were exempt from institutional review board (IRB) review (ethical committee of 'Comité de Protection des Personnes of Paris, Ile-de-France' FIBROFRANCE project. CPP-IDF-VI, 10–1996-DR-964, DR-2012-222 and USA-NCT01927133).

This project was funded by the European Grant EIT health ProCoP 20879, Patrice Cacoub being the awarded author.

All the coauthors have reviewed this manuscript.

The data that support the findings of this study are fully available from the corresponding author, upon request.

I have a potential conflict of interest as the inventor of FibroTest, and founder of BioPredictive a spinoff company of Sorbonne University. The patent belongs to the French public organization Assistance Publique Hôpitaux de Paris.

Kind regards

Thierry Poynard

medRxiv preprint doi: https://doi.org/10.1101/2020.09.01.20186213; this version posted September 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

All rights reserved. No reuse allowed without permission.

Performance of serum apolipoprotein-All as a sentinel of Covid-19

2 3 4

1

Short title: Apolipoprotein-A1 decrease in Covid-19

5 6 7

- 8 Thierry Poynard^{1*}, Olivier Deckmyn^{2*}, Marika Rudler³, Valentina Peta², Yen Ngo², Mathieu
- Vautier⁴, Sepideh Akhavan⁵, Vincent Calvez⁶, Clemence Franc², Jean Marie Castille², Fabienne 9
- Drane², Mehdi Sakka⁶, Dominique Bonnefont-Rousselot⁶, Jean Marc Lacorte⁷, David 10
- 11 Saadoun⁴, Yves Allenbach⁴, Olivier Benveniste⁴, Frederique Gandjbakhch⁹, Julien Mayaux¹⁰
- Olivier Lucidarme¹¹, Bruno Fautrel⁹, Vlad Ratziu^{3,12}, Chantal Housset¹, Dominique 12
- 13 Thabut³ and Patrice Cacoub⁴

14

- 15 Authors' affiliations
- 1. Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne University, INSERM, Centre de 16
- 17 Recherche Saint-Antoine (CRSA), Institute of Cardiometabolism and Nutrition (ICAN)
- 18 2. BioPredictive, Research, Paris, France
- 19 3. AP-HP Pitié-Salpêtrière, Sorbonne University, Department of Hepatology, Paris, France
- 20 4. AP-HP Pitié-Salpêtrière, Sorbonne University, Department of Internal Medicine and Clinical 21 Immunology, Paris, France
- 22 5. AP-HP Pitié-Salpêtrière, Sorbonne University, Department of Virology, Paris, France
- 23 6. AP-HP Pitié-Salpêtrière, Sorbonne University, Department of Metabolic Biochemistry,
- Paris, France 24
- 25 7. AP-HP Pitié-Salpêtrière, Sorbonne University, Department of Biochemistry, Endocrinology
- 26 and Oncology, Paris, France
- 27 8. AP-HP Pitié-Salpêtrière, Sorbonne University, Institut of Cardiometabolism and Nutrition
- 28 ICAN. Paris. France
- 29 9. AP-HP Pitié-Salpêtrière, Sorbonne University, Department of Rhumatology, Paris, France
- 10. AP-HP Pitié-Salpêtrière, Sorbonne University, Department of Intensive Care, Paris, France 30
- 31 11. AP-HP Pitié-Salpêtrière, Sorbonne University, Department of Radiology, Paris, France
 - 12. INSERM Sorbonne University UMRS 1269 Nutriomique, service de Nutrition, APHP
- 32 *These authors contributed equally to this work.

33

- 34 Corresponding author: Thierry Poynard, Hepatology Groupe Hospitalier Pitie-Salpêtrière, 57
- Bd Hôpital 75013 Paris, France. thierry@poynard.com . +(33) Tel: 142161022 Fax: 35
- 36 142161427

37

Funding source: Grant EIT health ProCoP 20879 Pr Patrice Cacoub 38 **APHP** France

medRxiv preprint doi: https://doi.org/10.1101/2020.09.01.20186213; this version posted September 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Electronic word count: 3,997 words (Including legends)

40

Number of figures and tables: 3 figures. 2 tables.

Conflict of interest statement: a statement to declare any conflict of interest.

45 Thierry Poynard is the inventor of FibroTest, founder of BioPredictive, the patents belong to the public organization Assistance Publique-Hôpitaux de Paris. Olivier Deckmyn, Valentina 46 Peta, Yen Ngo, Jean Marie Castille, Fabienne Drane and Clemence Franc are full employees of 47 48 BioPredictive. The other authors have nothing to declare.

Authors' contribution

41 42

43 44

49 50 51

52

53

54

55

Thierry Poynard, M.D. PhD (Conceptualization: Lead; Data curation: Equal; Formal analysis: Equal; Funding acquisition: Equal; Investigation: Equal; Methodology: Lead; Project administration: Lead; Resources: Equal; Supervision: Lead; Validation: Lead; Visualization: Lead; Writing - original draft: Lead; Writing - review & editing: Lead)

- 56 Olivier Deckmyn, PhD (Conceptualization: Equal; Data curation: Equal; Methodology: Equal; Software: Lead;
- 57 Validation: Equal; Visualization: Equal; Writing – original draft: Equal; Writing – review & editing: Equal)
- 58 Marika Rudler, MD, PhD (Data curation: Equal; Investigation: Equal; Resources: Equal)
- 59 Valentina Peta, PhD (Data curation: Equal; Investigation: Equal; Resources: Equal; Writing original draft: Equal; 60 Writing review & editing: Equal)
- 61 Yen Ngo, MD PhD (Data curation: Equal; Investigation: Equal; Methodology: Equal; Validation: Equal)
- 62 Mathieu Vautier, MD (Data curation: Equal; Investigation: Equal; Resources: Equal)
- 63 Sepideh Akhavan, MD PhD (Data curation: Equal; Investigation: Equal; Resources: Equal; Validation: Equal)
- 64 Vincent Calvez, MD PhD (Resources: Equal; Supervision: Equal; Validation: Equal)
- 65 Clemence Franc, MS (Formal analysis: Equal; Investigation: Equal; Writing – original draft: Equal)
- 66 Jean Marie Castille, PhD (Funding acquisition: Equal; Project administration: Equal; Validation: Equal)
- 67 Fabienne Drane, Ms (Investigation: Equal; Resources: Equal; Validation: Equal)
- 68 Mehdi Sakka, MD PhD (Investigation: Equal; Resources: Equal; Validation: Equal)
- 69 Dominique Bonnefont-Rousselot, Md PhD (Resources: Equal; Supervision: Equal; Validation: Equal)
- 70 Jean Marc Lacorte, MD PhD (Resources: Equal; Supervision: Equal; Validation: Equal)
- 71 David Saadoun, MD PhD (Data curation: Equal; Investigation: Equal; Resources: Equal)
- 72 Yves Allenbach, MD PhD (Data curation: Equal; Investigation: Equal; Resources: Equal)
- 73 Olivier Benveniste, MD PhD (Investigation: Equal; Resources: Equal; Supervision: Equal)
- 74 Frederique Gandjbakhch, MD PhD (Data curation: Equal; Investigation: Equal; Resources: Equal)
- 75 Julien Mayaux, MD PhD (Data curation: Equal; Investigation: Equal; Resources: Equal)
- 76 Olivier Lucidarme, MD PhD (Investigation: Equal; Resources: Equal; Validation: Equal)
- 77 Bruno Fautrel, MD PhD (Investigation: Equal; Resources: Equal; Supervision: Equal)
- 78 Vlad Ratziu, MD PhD (Formal analysis: Equal; Investigation: Equal; Resources: Equal)
- 79 Chantal Housset, MD PhD (Formal analysis: Equal; Supervision: Equal; Validation: Equal; Writing - original 80 draft: Equal)
- 81 Dominique Thabut, MD PhD (Project administration: Equal; Resources: Equal; Supervision: Equal; Validation: 82
- 83 Patrice Cacoub, MD PhD (Conceptualization: Lead; Formal analysis: Lead; Funding acquisition: Equal;
- 84 Investigation: Equal; Project administration: Lead; Resources: Equal; Supervision: Lead; Validation: Lead;
- Visualization: Lead; Writing original draft: Equal; Writing review & editing: Equal)

medRxiv preprint doi: https://doi.org/10.1101/2020.09.01.20186213; this version posted September 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

All rights reserved. No reuse allowed without permission.

87 **Key Points**

- **Question:** Does serum apolipoprotein-A1 decrease could be a very early biomarker of SARS-
- 89 CoV-2 pandemic?
- 90 **Findings:** During the 30 weeks of 2020 we observed in two large cohorts of patients at risk of
- 91 liver fibrosis a highly significant decrease of serum apolipoprotein-A1, not observed in previous
- 92 years. This decrease was highly correlated to and in parallel with the daily increase in confirmed
- 93 Covid-19 cases, including the recovery period.
- 94 **Meaning:** Apolipoprotein-A1 could be used as a sentinel of the pandemic in existing routine
- 95 surveillance of the general population.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.01.20186213; this version posted September 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. 97

ABSTRACT

Background

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

Since 1920, a decrease in serum cholesterol has been identified as a marker of severe pneumonia. We have assessed the performance of serum apolipoprotein-A1, the main transporter of HDL-cholesterol, to identify the early spread of coronavirus disease 2019 (Covid-19) in the general population and its diagnostic performance for the Covid-19.

Methods

We compared the daily mean serum apolipoprotein-A1 during the first 30 weeks of 2020 in a population that is routinely followed for a risk of liver fibrosis risk in the USA (183,112 sera) and in France (18,316 sera) in relation to a local increase in confirmed cases, and in comparison to the same period in 2019 (respectively 234,881 and 26,056 sera). We prospectively assessed the sensitivity of this marker in an observational study of 136 consecutive hospitalized cases and retrospectively evaluated its specificity in 7,481 controls representing the general population.

Results

The mean serum apolipoprotein-A1 levels in these populations began decreasing in January 2020, compared to the same 30 weeks in 2019. This decrease was highly correlated to and in parallel with the daily increase in confirmed Covid-19 cases in the following 30 weeks, in both France and USA, including the June and mid-July recovery periods in France. Apolipoprotein-A1 at the 1.25 g/L cutoff had a sensitivity of 90.6% (95%CI84.2-95.1) and a specificity of 96.1% (95.7-96.6%) for the diagnosis of Covid-19. The area under the characteristics curve was 0.978 (0.957-0.988), and outperformed haptoglobin and liver function tests. The adjusted risk ratio for survival without transfer to intensive care unit was 5.61 (95%CI 1.02-31.0;P=0.04).

Conclusion

medRxiv preprint doi: https://doi.org/10.1101/2020.09.01.20186213; this version posted September 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Apolipoprotein-A1 could be both a sentinel of the pandemic in existing routine surveillance of the general population with no new blood sample, as well as a candidate predictor of suspected Covid-19 in multivariate analysis in cases with a negative virological test. NCT01927133, CER-2020-14. **Keywords:**

- SARS-CoV-2; COVID-19; ApoA1; HDL-cholesterol; A2M; haptoglobin; ALT, GGT;
- pandemic early biomarker; FibroFrance cohort

medRxiv preprint doi: https://doi.org/10.1101/2020.09.01.20186213; this version posted September 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

All rights reserved. No reuse allowed without permission. 131

Introduction

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

153

154

155

There is an urgent need to detect people in the general population who are at risk of being admitted to the hospital for Covid-19. Although viral nucleic acid testing and chest computed tomography are standard methods for diagnosing Covid-19 in patients with symptoms, these are time consuming. A review reported that there are only three models for predicting hospital admission in the healthy general population, and these are limited by a high risk of bias, and by using proxy outcomes.¹

In the meantime, several early detection tests of cytokine burst could be immediately available. In 1920, Harold A. Kipp found that a decrease in serum cholesterol was a marker of severe pneumonia.² One hundred years later, a meta-analysis confirmed that levels of highdensity lipoprotein cholesterol (HDL) and a level below the median of its transporter, apolipoprotein-A1, was associated with a two-fold increase in mortality in patients with severe sepsis (supplementaryFig1,supplementaryTable1).³ Its decrease seems to occur earlier than the increase in haptoglobin, another marker of sepsis. ^{4,5} Furthermore, unlike haptoglobin, which is synthesized mainly by the liver, apolipoprotein-A1 is synthesized by both the liver and the intestine.⁵ This hypolipidemia begins in Covid-19 patients with mild symptoms.^{6,7} Therefore, in the general population, apolipoprotein-A1 might be a sensitive marker of infection in asymptomatic subjects, in those without the pulmonary symptoms of standard Covid-19, or in patients with an intestinal route of infection (supplementaryFile1).^{8,9}

Methods.

152 **Ethics**

> The prospective observational study in Covid-19 patients was approved by CER-Sorbonne University IRB,CER-2020-14, with a signed informed consent. All of the previously published patient analyses from retrospective databases were non-interventional studies, without

medRxiv preprint doi: https://doi.org/10.1101/2020.09.01.20186213; this version posted September 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Supplementary blood samples, and were exempt from a review of the IRB 156 (NCT01927133, supplementary File2). The investigation was performed according to the 157 158 principles of the Declaration of Helsinki. All authors had access to the study data and reviewed 159 and approved the final manuscript. 160 Decrease of apolipoprotein-A1 161 We used three cohorts of sera from subjects at risk of liver fibrosis followed by FibroTest (FibroSure in USA, supplementaryFile2), 10 a large private-laboratories US cohort ("US-162 163 cohort"), a cohort with an intermediate risk of Covid-19 "(French-cohort") were patients being 164 followed in academic and private-laboratories, and a high-risk cohort which included patients 165 at the Pitié-Salpêtrière hospital Paris, France ("APHP-PSL"). The core temporal analysis 166 compared the first 30 weeks of consecutive anonymous sera 2020 vs. the sera 2019, from these 167 three routinely followed cohorts (supplementaryFile2, supplementaryFig2C). 168 Confounding factors Decrease in apolipoprotein-A1 may be due to direct liver toxicity from SARS-CoV-2. 11 but also 169 170 to drug-induced liver disease (DILI) caused by medications (supplementaryFile2, 171 **supplementaryTable2**). We analyzed the kinetics of alpha2-macroglobulin (A2M) a specific

Decrease in apolipoprotein-A1 may be due to direct liver toxicity from SARS-CoV-2, ¹¹ but also to drug-induced liver disease (DILI) caused by medications (**supplementaryFile2**, **supplementaryTable2**). We analyzed the kinetics of alpha2-macroglobulin (A2M) a specific marker of liver fibrosis, ¹⁰ and of haptoglobin, a sensitive biomarker of severe acute phase, as well in the US-cohort of all the other components, according to non-alcoholic fatty liver disease (NAFLD) sera, or chronic hepatitis C (HCV) sera(**supplementaryFile2**).

175 Daily apolipoprotein-A1 and spread of Covid-19

The number of confirmed Covid-19 cases in France and in the USA was assessed according to published data from the European Centre for Disease Prevention and Control (https://ourworldindata.org/coronavirus-data) (supplementaryFig2A ,supplementaryFig2B).

179 Sensitivity and prognostic value

172

173

174

176

177

medRxiv preprint doi: https://doi.org/10.1101/2020.09.01.20186213; this version posted September 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Sensitivity was assessed in a prospective study of Covid-19 patients hospitalized in APHP-PSL, 180 181 described in supplementaryFile2. The primary endpoint was the survival without transfer in 182 ICU at 28 days, adjusted on age, gender, haptoglobin, and liver tests. (supplementary Table 1, 183 supplementaryTable2,supplementaryFile1. 184 **Specificity** 185 We collected prospective data on apolipoprotein-A1 from and since the first cohort of alcoholic 186 liver disease in 1982, and from the FibroFrance cohort (supplementaryFile2). More recently, 187 we collected six cohorts, which allowed us to retrospectively validate the specificity in a large group of subjects (supplementaryFile2). 12-16 The measurements were all performed on fresh 188 189 prospectively collected serum and analyzed in the biochemistry unit of the APHP-PSL hospital, 190 with the same methods as the Covid-19 cases (supplementary Table 3). The core control 191 population was a group of healthy volunteers that was representative of the French population. ¹⁶ Forty-three patients without suspected Covid-19 were excluded (supplementaryTable4). In 192 193 order to identify a profile of patients with a possible intestinal route of infection, we compared 194 the subsets of patients with or without diarrhea. 195 Apolipoprotein-A1, haptoglobin, A2M, gammaglutamyl transpeptidase (GGT), alanine 196 aminotransferase (ALT) were assessed (supplementaryTable2,supplementaryFile1), following BioPredictive (Paris, France) analytical recommendations. ¹⁷ The virological methods 197 198 for the diagnosis used to diagnose SARS-CoV2 in respiratory samples, were detailed in 199 supplementaryFile2. 200 **Statistical methods** 201 The first primary endpoint was to demonstrate a significant decrease of the mean daily value of 202 apolipoprotein-A1 in the 30 weeks of the year 2020, vs. those of the year 2019. We defined a

significant decrease of apolipoprotein-A1 as below 1.25 g/L, the optimal cutoff defined by the

highest Youden index (sensitivity + specificity -1) in the severe patients. The daily proportion

203

medRxiv preprint doi: https://doi.org/10.1101/2020.09.01.20186213; this version posted September 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

of sera below this cutoff defined a significant risk of Covid-19. The second analysis was to

exclude confounding factors detailed in **supplementaryFile1**. We compared the linear regression curves with 95% confidence intervals (95%CI) between the mean daily levels of all markers, and the daily proportion of low apolipoprotein-A1, between the same 30 weeks periods per year, by the *F*-test. A significant difference was defined as P<0.001. The third primary endpoint was to assess the association between the spread of Covid-19 and the decrease in apolipoprotein-A1. The diagnostic performance of biomarkers was assessed using non-parametric AUROCs. The prognostic values were assessed by survival curves, using Kaplan-Meir method, compared by Logrank test (cutoff being the median of this context of use) and adjusted by Cox model. The repeated sera assessments were compared by repeated ANOVA and Tukey-Kramer multiple-comparison test. R and NCSS-2020 were used as statistical software.

Results

205

206

207

208

209

210

211

212

213

214

215

216

217218

- 220 Decrease of apolipoprotein-A1
- The mean daily levels of apolipoprotein-A1 decreased globally (**fig1A**) and in the three cohorts
- 222 (**fig1B**; all P<0.001), during the first 30 weeks of 2020. This was already highly significant in
- January 2020 in the US-cohort (lower panel), compared to first 30 weeks of 2019 and 2018.
- The mean daily proportion of sera with low apolipoprotein-A1 was 32.4% (95% CI 32.4-32.5)
- on 30 weeks, that is 5.1% higher vs. 26.8% (27.2-27.4;P<0.001) in 2019 (**fig1C**). There was no
- significant difference between the years 2019 and 2018 for the daily mean globally (**fig1A**), or
- by cohort (**fig1B**). The proportion of low apolipoprotein-A1, in 2018 was 26.5%(26.3-26.6),
- 228 that is a small 0.8% difference vs. the year 2019 (**fig1C**).
- 229 Confounding factors

medRxiv preprint doi: https://doi.org/10.1101/2020.09.01.20186213; this version posted September 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

All rights reserved. No reuse allowed without permission.

The same significant kinetics in apolipoprotein-Al levels were observed after stratification of 230 231 the regression curves for gender and age in the three cohorts (supplementaryFig3). The US-

cohort was the only sample that had the necessary power to compare these two factors together between 2020 and 2019 and 2018 (fig1D), and in the subset of patients with HCV (supplementaryFig3C). Apolipoprotein-A1 decrease was similar during Covid-19 spread versus 2019 and 2018 in the US-cohort(supplementaryFile2, supplementaryFig3).

The kinetics of apolipoprotein-A1 were not associated with those of haptoglobin

237 (supplementaryFig4).

232

233

234

235

236

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

For A2M, there was in the US-cohort only a significant lower mean serum value, when compared to 2019 and even more compared to 2018 (supplementaryFig5A), and detailed in supplementaryFig5, and highest in HCV vs. NAFLD sera. After adjustment on age and gender there was no significant decrease of A2M between 2020 and 2019 (supplementaryFig5).

The other significant differences were, in the French-cohorts, GGT increased during the pandemic peak and returned to previous years' value thereafter (supplementaryFig6), and an increase in ALT in April 2020, in the US-cohort (supplementaryFig7).

No significant changes were observed for total cholesterol (supplementaryFig8), triglycerides (supplementaryFig9), fasting glucose (supplementaryFig10), weight (supplementaryFig11) and height (supplementaryFig12).

Temporal associations between Covid-19 cases and apolipoprotein-A1

The daily mean number of confirmed Covid-19 cases paralleled about 10 days after the daily proportion of low apolipoprotein-A1 in sera. In USA, the first ten Covid-cases were declared mid-January 2020, when the proportion of low apolipoprotein-A1 had already increase by several percent (**fig1E**). The first peak of cases (n=50,000) was reached mid-April medRxiv preprint doi: https://doi.org/10.1101/2020.09.01.20186213; this version posted September 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

All rights reserved. No reuse allowed without permission.

(supplementaryFig2B), and the first peak of low apolipoprotein-A1 (37.0%) on April 7th

254

(fig1E, supplementaryFile2).

255

256

257

258

259

260

263

264

266

267

270

271

272

274

275

276

277

278

In France, the first ten Covid-cases were declared first week of March 2020 (supplementaryFig2A), when the proportion of low apolipoprotein-A1 started to increase by

several percent (**fig1C**). The first peak of cases (n=7,000) was reached mid-April

(supplementaryFig2A), as well as the first peak of low apolipoprotein-A1 (40.0%) on April

14th (fig1C, supplementaryFile2).

261 Diagnostic performance of apolipoprotein-A1

262 A total of 136 consecutive patients with severe Covid-19, but who did not require ICU were

include. Their characteristics and were similar to those published in such severity profiles

(Table 2, supplementary File 3).

265 The characteristics of patients included for the assessment of specificity are presented in

supplementaryTable3, the differences between characteristics of the subsets in

supplementary Table 3, in fig 2A for the median value of apolipoprotein-A1 and in fig 2B for

268 haptoglobin at inclusion.

269 The area under the characteristics curve (AUROC;95%CI) in 136 Covid-19 cases and 7,481

controls was 0.978(0.957-0.988), which outperformed haptoglobin and liver function tests

(**fig2C**). Apolipoprotein-A1 at a cutoff of 1.25 g/L, had the best Youden index (86.7%) with a

sensitivity of 90.6%(84.2-95.1) and a specificity of 96.1%(95.7-96.6) for the diagnosis of

273 Covid-19.

For a prevalence of 1.8% (136/7617;1.5-2.1) of Covid-19 cases, the positive predictive value

was 30.0%(25.6-34.7) and the negative predictive value was 99.8%(99.7-99.9). The adjusted

predictive values according to prevalence predicted in the French population, ¹⁶ were detailed

in supplementaryFile2 as well as the specificity-sensitivity including blood donors

(supplementaryFig12), and patients with rheumatological disease (supplementaryFig13),

medRxiv preprint doi: https://doi.org/10.1101/2020.09.01.20186213; this version posted September 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

and the integrated six databases (supplementaryFig14), and the sensitivity in the 19 patients 279 280 with negative viral nucleic acid testing. 281 The prognostic value of apolipoprotein-A1 at inclusion for predicting the primary outcome was significant, risk-ratio (RR;95%CI) =5.61 (1.02-31.0;P=0.04), adjusted on age (1.04;1.01-282 283 1.07;P=0.04), GGT (2.88;1.01-8.19;P=0.04). The 71 patients with apolipoprotein-A1 284 value>=0.84 g/L, the median value at inclusion, had a significant higher survival without ICU 285 (93.0%;87.0-98.9) than the 65 patients with lower value (75.8%; 65.1-86.5; P=0.02) (**fig2D**). 286 Repeated assessments of 305 sera (supplementaryFig15) showed that in patients who survived 287 without ICU, the mean apolipoprotein-A1 raised significantly already at 10 days, as well as the 288 16 patients who survived after their transfer to ICU. 289 The prevalence of diarrhea on initial presentation was 29 out of 131 cases (22.1%;95% CI 15.4-290 30.2). In this subset, the only significant difference was a lower median number of polynuclear 291 leucocytes (supplementaryTable5, supplementaryFile2). 292 293 294 **Discussion** 295 Our study shows in three cohorts of patients at risk of liver fibrosis, that apolipoprotein-A1 had 296 a highly significant decrease in 2020 vs previous years, and a highly significant negative daily 297 time-related association with the number of Covid-19 cases. Apolipoprotein-A1 decrease had 298 a high sensitivity in prospective hospitalized patients, with a high specificity in retrospective 299 controls, and an independent prognostic value for the survival without transfer to ICU. These 300 results have certain strengths and limitations. 301 Decrease of apolipoprotein-A1 in 2020 302 The originality of these results was not the decrease in apolipoprotein-A1 during the peak of 303 the pandemic in April, as very low levels of HDL-cholesterol in sera collected in Covid-19

were known in severe pneumonia since 1920 (supplementaryTable1).² More intriguing was

medRxiv preprint doi: https://doi.org/10.1101/2020.09.01.20186213; this version posted September 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

All rights reserved. No reuse allowed without permission.

the very early decrease observed since January 2020 in the USA when the number of Covid-19 305 306 cases was unknown. The first known Covid-19 patient was detected on 27/12/2019 and 307 19/01/2020 in France and the USA, respectively(supplementaryFile3). The larger sample size 308 of the US surveillance population, compared to the French, allowed detection of a significant 309 1% increase in the proportion of subjects possibly infected using the 1.25 g/L cutoff in January 310 (fig1C), without any inflammatory signal using haptoglobin. We hypothesized that the SARS-311 CoV2 virus influenced the liver or intestinal synthesis of apolipoprotein-A1, in asymptomatic 312 patients or in those with unusual mild symptoms. 313 Confounding factors 314 The decrease of apolipoprotein-A1 in 2020 vs. previous years, as well as the time-related 315 association of apolipoprotein-A1 in 2020 and Covid-19 might be due to numerous confounding 316 factors. In the context of the pandemic we used cohorts of subjects requiring surveillance of 317 liver fibrosis biomarkers which represent at least 30% of the general adult population in the 318 USA and in France. In these cohorts 70% of the subjects had no or minimal fibrosis. The 319 decrease in apolipoprotein-A1 in 2020 compared to 2019, and 2018 cannot be explained by bias 320 due to gender, age, the cause of liver disease (table1, supplementaryFile3), and the severity 321 of liver diseases (supplementaryFile4). The prevalence of severe cases cannot explain the 322 significant decrease in apolipoprotein-A1 already observed in January 2020. GGT a very 323 sensitive liver biomarkers did not change during the first 3 months (supplementaryFig6). 324 Finally, in these severe liver diseases, haptoglobin should be also significantly decreased 325 (fig2A), which was not observed. 326 In the US-cohort the proportion of sera with NAFLD was increased by 1.8% in 2020 vs 2019 327 (table1). However, after stratification for age and gender, no significant changes were observed 328 for all other biomarkers (supplementaryFig8,supplementaryFig10,

supplementaryFig11,supplementaryFile12). ALT was the only biomarker of the liver tests

medRxiv preprint doi: https://doi.org/10.1101/2020.09.01.20186213; this version posted September 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Which increased significantly at the 13 week of 2020, above the usual mean value observed in 330 331 2019 (supplementaryFile7). This increase in ALT was not associated with any other changes 332 (supplementaryFig10, supplementaryFig11,supplementaryFig12). We have no clear 333 explanation. We hypothesize that another confounding factor could be a DILI, including oral 334 acetaminophen or hydroxychloroquine misuse during the pandemic. Such factor could explain an increase in ALT, without increase in haptoglobin, in subjects with mild symptoms. 335 336 The absence of haptoglobin change (supplementaryFig4) associated with the linear 337 apolipoprotein-A1 decrease (fig1B), has never been described before. It was known that in patients with severe fibrosis these two proteins decrease. 10 It was also known that in severe 338 339 pneumonia the haptoglobin increase was associated to the apolipoprotein-A1 decrease 340 (supplementary Table 1), as we observed in the cohorts with high prevalence of severe Covid-341 19 (**fig2B**)(**supplementaryFile3**). The 30 weeks followup permitted to see the return to normal 342 values of haptoglobin in these cohorts, associated to the decrease of severe Covid-19 cases 343 admissions (supplementaryFig4A). Furthermore, the recovering patients followed by repeated 344 sera in the prospective study, had both a significant increase of apolipoprotein-A1 345 (supplementaryFig15B) and a significant decrease in haptoglobin (supplementaryFig15D), 346 10 days after inclusion. 347 Temporal associations between Covid-19 confirmed cases and apolipoprotein-A1 decrease 348 Our results (**fig1C**) suggest that the spread of the pandemic in the US-cohort would be at least 349 around 5.6%, and at least of 4.3% in the French-cohort. In France, this estimate does not differ 350 from the recent French model that predicted a rate of infection of between 2.8% to 7.2% in the 351 general population.¹⁸ 352 This temporal association of low apolipoprotein-A1 with the number of confirmed cases, 353 persisted in the two different pandemic changes. In France, after the national lockdown the

proportion of low apolipoprotein-A1 returned to the cohort usual 2018-2019 values in June

medRxiv preprint doi: https://doi.org/10.1101/2020.09.01.20186213; this version posted September 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

All rights reserved. No reuse allowed without permission.

Together with the dramatic regression of confirmed cases, still maintained in July. In the US, 355 the apolipoprotein A1 and confirmed cases had the same kinetics with the dramatic increase in 356

Specificity of apolipoprotein-A1

April and a plateau in June, still ongoing in July (fig1E).

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

There is a high risk of overestimating the specificity of a test in Covid-19 when the participants enrolled in the studies might not be representative of targeted populations. However, our previous cohorts of patients with severe liver diseases allowed us to identify the major risks of a significant decrease in apolipoprotein-A1 (false positives), mainly due to severe hepatic insufficiency and severe fibrosis. An impact of malnutrition on apolipoprotein-A1 values, was not possible as no changes in weight and height were observed.

Sensitivity of apolipoprotein-A1

There is also a high risk of overestimating the sensitivity. It is difficult to confirm the sensitivity for asymptomatic infection, due to the absence of validations of SARS-CoV2antibodies. To validate the sensitivity of apolipoprotein-A1, a large number of asymptomatic "apparently healthy" subjects who are positive for SARS-CoV-2 viral nucleic acid testing is needed. Our patients included with Covid-19 symptoms had a median of 70 years of age and were severe enough to justify admission to hospital, but none of them required mechanical ventilation at admission, 86% survived, only 6% were transferred to the intensive care unit, and 9% died (table1). The sensitivity in the prospective part of our study was similar in the 19 patients who were negative for viral nucleic acid testing (94.7%) to that in positive patients (89.9%). Thus, a simple measurement of apolipoprotein-A1 could be useful for clinicians due to the high percentage of false negatives in available viral nucleic acid testing. ¹⁸ Apolipoprotein-A1 or HDL-cholesterol are already being assessed in many large ongoing studies in patients with chronic diseases, which could rapidly validate our results.

Prognostic performance

medRxiv preprint doi: https://doi.org/10.1101/2020.09.01.20186213; this version posted September 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

All rights reserved. No reuse allowed without permission.

The univariate prognostic value of apolipoprotein-Al was confirmed (fig2D) but to our 380 381 knowledge, it was the first time that its prognostic value persisted after adjustment by age, a 382 marker of acute inflammation (haptoglobin), a sensitive marker of liver injury (GGT), and a marker of liver fibrosis (A2M). Among patients with recovery, there was a significant increase 383 384 apolipoprotein-A1 10 days after admission (supplementaryFig15). Therefore, 385 apolipoprotein-A1 measurement could help for the decision to transfer to ICU. 386 Mechanisms of the early decrease in apolipoprotein-A1 before recognition of the pandemic 387 We never observed such profile of biomarkers in our experience since 2001 with more than three million of FibroTest assessed in liver diseases (supplementaryFile1). 10,12-17 388 389 Although the mechanisms explaining the decrease in apolipoprotein-A1 in late severe Covid-390 19 pneumonia are known (**supplementaryTable1**), the reason for the early decrease before the 391 acute phase, when haptoglobin remained normal is unclear. In patients with severe pneumonia, 392 apolipoprotein-A1 decrease was associated with acute inflammation and the "cytokine storm" 393 with an increase in IL6 and acute phase proteins such as CRP and haptoglobin. This dissociation 394 suggests that different mechanisms play a role in the early influence of the SARS-CoV2 virus 395 on the synthesis of apolipoprotein-A1, and the intestine could be more involved than the liver. 396 The SARS-CoV2 virus could impact several pathways leading to a decrease in the intestinal synthesis and absorption of apolipoprotein-A1 in the small intestine resulting in the decrease in 397 398 serum.³⁻⁹ These mechanisms are discussed in **supplementaryFile1**. The first could the 399 inhibition of lysophosphatidylcholine-acyltransferase-3 activity. There is evidence of direct 400 SARS-CoV2 infection of the endothelial cell and diffuse endothelial inflammation in the

intestine. 7,8,9 SARS-CoV2 uses angiotensin-converting enzyme-2 receptor (ACE-2) expressed

on endothelial cells, to infect the host, widely expressed in the lung, intestine and liver. 9,20 The

second mechanism could be an impact of the virus through the intestinal mucus.²¹

Apolipoprotein-A1 is released as a free apolipoprotein from the apical side of enterocytes into

401

402

403

medRxiv preprint doi: https://doi.org/10.1101/2020.09.01.20186213; this version posted September 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

All rights reserved. No reuse allowed without permission.

the lumen in the fasting state. Apolipoprotein-Al had faster turnover in mucus, which could be

a target for SARS-CoV2.7,8,21

Conclusion

405

406

407

408

409

410

411

412

413

414

415

416

Despite the limitations of this study, these results suggest that apolipoprotein-A1 could be a component of multi-analyte Covid-19 diagnostic and prognostic tests. It could also help to manage patients with a clinical suspicion of Covid-19 and a negative virological test. These results must be validated in independent large cohorts, ideally with virologic and efficiency endpoints. The role of SARS-CoV2 in the possible "asymptomatic" decrease in apoliprotein-A1 could be related to intestinal infection without or before overt pulmonary disease. Finally, one hundred years after surrogate sentinel HDL-cholesterol for pneumonia,² apolipoprotein-A1 for the second time in a century, could be "one of the early warning systems that alert the world to potential outbreaks".22

medRxiv preprint doi: https://doi.org/10.1101/2020.09.01.20186213; this version posted September 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

All rights reserved. No reuse allowed without permission.

- 417 References
- 1. Wynants L, Van Calster B, Bonten MMJ, et al. Prediction models for diagnosis and prognosis
- of Covid-19 infection: systematic review and critical appraisal. BMJ 2020;**369**:m1328.
- 420 2. Kipp HA. Variation in the cholesterol content of the serum in pneumonia. J Biol Chem 1920;
- **42**1 **44**:215-237.
- 3. Liu SH, Liang HY, Li HY, et al. Effect of low high-density lipoprotein levels on mortality
- of septic patients: A systematic review and meta-analysis of cohort studies. World J Emerg
- 424 Med 2020;**11**:109–116.
- 425 4. Delanghe JR, Langlois MR, Boelaert JR, et al. Haptoglobin polymorphism, iron metabolism
- and mortality in HIV infection. AIDS 1998;12:1027-32.
- 5. Yang H, Wang Y, et al. The haptoglobin beta subunit sequesters HMGB1 toxicity
- in sterile and infectious inflammation. J Intern Med 2017;**282**:76-93.
- 6. Wei X, Zeng W, Su J, et al. Hypolipidemia is associated with the severity of COVID-19. J
- 430 Clin Lipidol. 2020;**14**:297-304.
- 7. Cao X, Yin R, Albrecht H,et al. Cholesterol: A new game player accelerating endothelial
- 432 injuries caused by SARS-CoV-2? Am J Physiol Endocrinol Metab. 2020;**319**:E197-E202.
- 8. Lamers MM, Beumer J, van der Vaart J, et al. SARS-CoV-2 productively infects human
- gut enterocytes. Science. 2020; eabc1669.
- 9. Ding S, Liang TJ. Is SARS-CoV-2 Also an enteric pathogen with potential fecal-oral
- 438 Transmission? A COVID-19 virological and clinical review. Gastroenterology
- 439 2020;**159**:53-61.

433

- 10. Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients
- with hepatitis C virus infection: a prospective study. Lancet 2001; **357**:1069-75.
- 11. Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet
- 443 Gastroenterol Hepatol 2020; **5**:428-430.
- 12. Peta V, Tse C, Perazzo H, et al. Serum apolipoprotein A1 and haptoglobin, in patients with
- suspected drug-induced liver injury (DILI) as biomarkers of recovery. PloS One 2017;
- 446 **12**:e0189436.
- 13. Rudler M, Mouri S, Charlotte F, et al. Validation of AshTest as a non-invasive alternative
- 448 to transjugular liver biopsy in patients with suspected severe acute alcoholic hepatitis. PLoS
- 449 One 2015; **10**:e0134302.
- 450 14. Perazzo H, Pais R, Munteanu M, et al. Variability in definitions of transaminase upper limit
- of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic
- hepatitis C: "APRI c'est fini?". Clin Res Hepatol Gastroenterol 2014; **38**:432-439.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.01.20186213; this version posted September 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

15. Church RJ, Kullak-Ublick GA, Aubrecht J, et al. Candidate biomarkers for the diagnosis

- 453
- 454 and prognosis of drug-induced liver injury: An international collaborative effort. Hepatology
- 455 2019; **69**:760-773.
- 456 16. Poynard T, Lebray P, Ingiliz P, et al. Prevalence of liver fibrosis and risk factors in a general
- 457 population using non-invasive biomarkers (FibroTest). BMC Gastroenterol 2010; 10:40.
- 458 17. Poynard T, Munteanu M, Deckmyn O, et al. Applicability and precautions of use of liver
- 459 injury biomarker FibroTest. A reappraisal at 7 years of age. BMC Gastroenterol. 2011;11:39.
- 460 18. Salje H, Tran Kiem C, Lefrancq N, et al. Estimating the burden of SARS-CoV-2 in France
- 461 2020;368:6498. Science. 2020;eabc3517.
- 462 19. Li Y, Yao L, Li J, et al. Stability issues of RT-PCR testing of SARS-CoV-2 for
- hospitalized patients clinically diagnosed with COVID-19. J Med Virol 2020; 92:903-908. 463
- 20. Xu H, Zhong L, Deng J, et al. High expression of ACE2 receptor of 2019-nCoV on the 465
- 466 epithelial cells of oral mucosa. Int J Oral Sci 2020;12:8.
- 468 21. Danielsen EM, Hansen GH, Rasmussen K, et al. Apolipoprotein A-1 deposition in, and
- 469 release from, the enterocyte brush border: a possible role in transintestinal cholesterol efflux
- 470 (TICE)? Biochim Biophys Acta 2012; 1818:530-536.
- 471 22. Gates B. Responding to Covid-19.A Once-in-a-Century Pandemic? New Engl J Med 2020;
- **382**:1677-1679. 472

464

467

medRxiv preprint doi: https://doi.org/10.1101/2020.09.01.20186213; this version posted September 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Table1. Characteristics of the Sera included in US and French-cohorts

Characteristics	2020	2019	P-Value
US-cohort	N=183,112	N=234,881	
Median age [IQR)	54.1 [40.4-63.3]	55.0 [41.7-63.3]	< 0.001
Age category n (%)			< 0.001
< 50 year	75,782(41.4)	90,853 (38.5)	
50 to <70 year	88,597 (48.4)	121,757 (51.8)	
>= 70 year	18,733 (10.2)	22,771 (9.7)	
Male sex (%)	103,672 (56.6)	131,056 (55.8)	< 0.001
Apolipoprotein-A1<1.25 g/L (%)	59,419 (32.4)	62,898 (26.8)	< 0.001
Median laboratory (IQR)			
Apolipoprotein-A1 g/L	1.37 [1.19-1.58]	1.41 [1.23-1.68]	< 0.001
Haptoglobin g/L	1.23 [0.82-1.68]	1.23 [0.82-1.69]	0.72
Alpha-2-macroglobulin g/L	2.16 [1.65-2.93]	3.07 [1.70-3.07]	< 0.001
GGT IU/L	36 [21-77]	38 [21-79]	0.87
ALT IU/L ¹	38 [22-70]	38 [23-68]	< 0.001
Total bilirubin micromol/L	6.84 [5.13-10.26]	6.84 [5.13-10.26]	0.01
Fibrosis stage by FibroTest (%)			< 0.001
F0	94,170 (51.4)	116,666 (49.7)	
F1	36,738 (20.1)	47,123 (20.1)	
F2	13,330 (7.3)	17,834 (7.6)	
F3	17,914 (9.8)	24,514 (10.4)	
F4	19,648 (10.7)	27,030 (11.5)	
Non interpretable	1,312 (0.7)	1,714 (0.7)	
NAFLD (surveillance by NASH-FibroTest) ²	N=37,298 (20.2)	N=42,271 (18.0)	< 0.001
Weight (Kg)	88.9 (74.8-105.2)	88.5 (74.8-104.3)	0.003
Aspartate amino transferase (AST)	34 (25-52)	34 (25-52)	0.55
Total cholesterol	4.53 (3.80.5.33)	4.53 (3.80-5.28)	0.001
Triglycerides	1.57 (1.13-2.24)	1.55 (1.11-2.21)	0.02
Fasting glucose	5.67 (5.06-6.89)	5.61 (5.06-6.78)	< 0.001
Table 3 continued	` '	` '	
French-cohort	N= 18,316	N=26,056	
Median age [IQR)	51.5 (41.2-64.4)	52.6 (39.7-63.1)	< 0.001
Age category n (%)			< 0.001
< 50 year	7,514 (40.9)	11,517 (44.2)	
50 to <70 year	8,187 (44.4)	11,340 (43.5)	
>= 70 year	2,615 (14.3)	3,199 (14.3)	
Male sex (%)	10,619 (58.0)	14,908 (57.2)	< 0.001
Apolipoprotein-A1<1.25 g/L (%)	5,694 (31.1)	7,057 (27.1)	< 0.001
Median laboratory (IQR)	, , ,	, , , , ,	
Apolipoprotein-A1 g/L	1.38 (1.20-1.59)	1.40 (1.23-1.61)	< 0.001
Haptoglobin g/L	1.18 (0.79-1.62)	1.15 (0.78-1.57)	< 0.001
Alpha-2-macroglobulin g/L	1.96 (1.52-2.61)	2.01 (1.56-2.69)	< 0.001
GGT IU/L	36 (21-79)	34 (20-73)	< 0.001
ALT IU/L	31 (21-50)	31 (21-50)	0.42
Total bilirubin micromol/L	8.7 (6-12)	8.7 (6-12)	0.20
Fibrosis stage by FibroTest (%)	J., (J. 12)	o., (o 12)	JU
	9.437 (51.5)	13.671 (52.5)	< 0.001
F0	9,437 (51.5) 4 080 (22.3)	13,671 (52.5) 5 708 (21.9)	< 0.001
F0 F1	4,080 (22.3)	5,708 (21.9)	< 0.001
F0 F1 F2	4,080 (22.3) 1,328 (7.3)	5,708 (21.9) 1,877 (7.2)	<0.001
F0 F1 F2 F3	4,080 (22.3) 1,328 (7.3) 1,664 (9.1)	5,708 (21.9) 1,877 (7.2) 2,263 (8.7)	<0.001
F0 F1 F2 F3 F4	4,080 (22.3) 1,328 (7.3) 1,664 (9.1) 1,655 (9.0)	5,708 (21.9) 1,877 (7.2) 2,263 (8.7) 2,336 (9.0)	<0.001
F0 F1 F2 F3 F4 Non interpretable	4,080 (22.3) 1,328 (7.3) 1,664 (9.1) 1,655 (9.0) 190 (0.8)	5,708 (21.9) 1,877 (7.2) 2,263 (8.7) 2,336 (9.0) 201 (0.8)	
F0 F1 F2 F3 F4 Non interpretable NAFLD (surveillance by NASH-FibroTest) ²	4,080 (22.3) 1,328 (7.3) 1,664 (9.1) 1,655 (9.0) 190 (0.8) 4152 (19.2)	5,708 (21.9) 1,877 (7.2) 2,263 (8.7) 2,336 (9.0) 201 (0.8) 6,110 (20.4)	<0.001
F0 F1 F2 F3 F4 Non interpretable NAFLD (surveillance by NASH-FibroTest) ² Weight	4,080 (22.3) 1,328 (7.3) 1,664 (9.1) 1,655 (9.0) 190 (0.8) 4152 (19.2) 83 (71-97)	5,708 (21.9) 1,877 (7.2) 2,263 (8.7) 2,336 (9.0) 201 (0.8) 6,110 (20.4) 83 (71-97)	<0.001 0.41
F0 F1 F2 F3 F4 Non interpretable NAFLD (surveillance by NASH-FibroTest) ² Weight Aspartate amino transferase (AST)	4,080 (22.3) 1,328 (7.3) 1,664 (9.1) 1,655 (9.0) 190 (0.8) 4152 (19.2) 83 (71-97) 30 (23-42)	5,708 (21.9) 1,877 (7.2) 2,263 (8.7) 2,336 (9.0) 201 (0.8) 6,110 (20.4) 83 (71-97) 30 (23-41)	<0.001 0.41 0.47
F0 F1 F2 F3 F4 Non interpretable NAFLD (surveillance by NASH-FibroTest) ² Weight Aspartate amino transferase (AST) Total cholesterol	4,080 (22.3) 1,328 (7.3) 1,664 (9.1) 1,655 (9.0) 190 (0.8) 4152 (19.2) 83 (71-97) 30 (23-42) 4.79 (4.00-5.55)	5,708 (21.9) 1,877 (7.2) 2,263 (8.7) 2,336 (9.0) 201 (0.8) 6,110 (20.4) 83 (71-97) 30 (23-41) 4.75 (4.00-5.62)	<0.001 0.41 0.47 0.30
F0 F1 F2 F3 F4 Non interpretable NAFLD (surveillance by NASH-FibroTest) ² Weight Aspartate amino transferase (AST)	4,080 (22.3) 1,328 (7.3) 1,664 (9.1) 1,655 (9.0) 190 (0.8) 4152 (19.2) 83 (71-97) 30 (23-42)	5,708 (21.9) 1,877 (7.2) 2,263 (8.7) 2,336 (9.0) 201 (0.8) 6,110 (20.4) 83 (71-97) 30 (23-41)	<0.001 0.41 0.47

medRxiv preprint doi: https://doi.org/10.1101/2020.09.01.20186213; this version posted September 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Rating glucose

All rights reserved. No reuse allowed without permission (5.17-6.90) 0.87

¹ Not normal distribution, the means of ALT were in 2020 43.4 IU/L vs 42.7 IU/L in 2019

² NASH-FibroTest included more components than FibroTest: weight, aspartate aminotransferase, total cholesterol, triglycerides, and fasting glucose

medRxiv preprint doi: https://doi.org/10.1101/2020.09.01.20186213; this version posted September 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Table2. Characteristics of Covid-19 patients of the prospective study.

Characteristics COV	ID-19 diagnostic			
	PCR positive	PCR negative Adjudicated	P value	Total
Number n (%)	117 (100%)	19 (100%)		136
Median age (IQR) year	72 (57-82)	65.1 (49-74)	0.15	72 (59-83)
Age category			0.16	
<50 year	14 (12.0)	5 (26.4)		19 (14.0)
50 to <70 year	37 (31.6)	7 (36.8)		44 (32.3)
>=70 year	66 (56.4)	7 (36.8)	0.70	73 (53.7)
Male sex	66 (56.4)	12 (63.2)	0.58	78 (57.4)
Geographic origin	(7 (57 2)	14 (72.7)	0.53	01 (50 ()
Caucasian Subsaharan	67 (57.3)	14 (73.7)		81 (59.6)
North African, Middle East	17 (14.5) 20 (17.1)	1 (5.3) 2 (10.5)		18 (13.2) 22 (16.9)
Asian	13 (11.1)	2 (10.5)		15 (11.0)
Oxygen-support category	13 (11.1)	2 (10.3)	0.75	13 (11.0)
Invasive oxygen support	0	0	0.73	0 (0-0)
Noninvasive oxygen support	82 (70.1)	14 (73.7)		96 (70.6)
None	35 (29.9)	5 (26.3)		40 (29.4)
Coexisting conditions	20 (2).))	c (20.5)		(=>)
Hypertension	65 (55.6)	9 (47.4)	0.51	74 (54.4)
Diabetes	32 (27.4)	3 (15.8)	0.29	35 (25.7)
Hyperlipidemia	32 (27.4)	7 (36.8)	0.40	39 (28.7)
Liver disease	11 (9.4)	4 (21.1)	0.13	15 (11.03)
Pulmonary disease	13 (11.6)	1 (5.6)	0.44	14 (10.8)
Severe disease associated	64 (55.2)	11(57.9)	0.82	75 (55.6)
Tobacco (ongoing or stopped)	35 (29.9)	8 (42.1.3)	0.29	43 (31.6)
Alcohol consumption	15 (12.9)	5 (26.3)	0.13	20 (14.8)
Initial presentation				
Anosmia (13 missing)	12 (11.1)	3 (20.0)	0.32	15 (12.2)
Ageusia (13 missing)	16 (14.8)	3 (20.0)	0.60	19 (15.5)
Headache (13 missing)	10 (9.3)	4 (26.7)	0.05	14 (11.4)
Dyspnea (12 missing)	59 (54.1)	8 (53.3)	0.95	67 (54.0)
Wheezing (12 missing)	3 (2.75)	0 (0.00)	0.52	3 (2.42)
Cough without spitting (12 missing)	47 (43.1)	6 (40.0)	0.82	53 (42.7)
Cough with spitting (12 missing)	18 (16.5)	2 (13.3)	0.75	20 (16.1)
Fatigue	61 (56.5)	8 (53.3)	0.82	69 (59.1)
Time clinic-inclusion (days)	8 (5-13.8)	11 (9-16.5)	0.13	9 (5-14)
Followup (days)	38 (27-53)	28 (26-36)	0.05	32 (27-49)
BMI (Kg/m²)	25 (23-29)	24 (22-28)	0.56	25 (23-28)
Apolipoprotein <= 1.25g/L	104 (88.9)	19 (100)	0.13	123 (90.4)
Median laboratory (IQR)	0.05 (0.72.1.06)	0.74 (0.61.0.07)	0.06	0.04 (0.70.1.02)
Apolipoprotein-A1 g/liter	0.85 (0.73-1.06)	0.74 (0.61-0.87)	0.06	0.84 (0.70-1.03)
Haptoglobin g/liter	3.16 (2.20-4.19) 1.49 (1.24-2.06)	3.18 (1.59-3.86)	0.59	3.16 (2.22-4.08)
Alpha-2 macroglobulin g/liter	,	1.46 (1.12-2.01)	0.41	1.49 (1.22-2.05)
GGT IU per liter ALT IU per liter	47 (28-114) 29 (20-47)	58 (32-102) 40 (15-57)	0.27 0.80	49 (30-114) 31 (20-51)
Total bilirubin micromol/L	7 (6-8)	9 (8-13)	0.00	8 (5-12)
Platelets 10 ⁶ per ml	211 (162-278)	279 (194-330)	0.01	221 (164-287)
Creatinine µmol per liter	78 (62-103)	78 (70-120)	0.97	78 (63-103)
Fasting glucose	6 (5.4-8.0)	6.6 (5.2-7.9)	0.38	6.1 (5.4-7.9)
Albumin g/L (18 missing)	31(27-33)	29 (27-39)	0.89	30 (27-33)
Procalcitonin (17 missing)	0.13 (0.08-0.27)	0.14 (0.09-0.23)	0.98	0.13 (0.09-0.27)
C-reactive protein (13 missing)	56 (20.3-95.6)	101 (15.4-252.9)	0.21	59 (20.3-102.3)
InterLeukin-6 (38 missing)	31 (13.5-55.2)	29 (8.05-119)	0.96	31 (12.3-55.5)
CPK (18 missing)	101 (51.5-243.3)	47.5 (37.5-127)	0.05	94 (45.8-233)
AST (11 missing)	44 (30-60)	34 (25-42)	0.04	41 (30-59)
LDH (16 missing)	347 (278-419)	353 (289-440)	0.68	347 (278-420)
D-dimer (24 missing)	1050 (550-2030)	1570 (1140-3980)	0.09	1125 (570-2158)
Troponin (14 missing)	16.4 (9.85-34.63)	17.2 (9.56-36.5)	0.99	16.4 (9.85-34.63)
Prothrombin time (16 missing)	92 (83-100)	82 (39-89)	0.005	90 (81-100)
White cells				
Neutrophil missing (14 missing)	4185 (2773-6145)	5945 (3963-7550)	0.05	4420 (2928-6200)
Eosinophil (12 missing)	0 (0-30)	10 (0-150)	0.14	0.05 (0-30)

medRxiv preprint doi: https://doi.org/10.1101/2020.09.01.20186213; this version posted September 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Lymphocyte (14 missing)	All rights reserved. No r	euse allowed without perm	0.25	975 (685-1295)
Hemoglobin g/L (12 missing)	12 (11.2-13.6)	12 (10.5-14.7)	0.64	12 (11.1-13.8)
Treatment at risk of DILI				
Paracetamol oral (2-4 g/day)	43 (36.8)	5 (26.3)	0.38	48 (35.3)
Antibiotics	91 (77.8)	15 (78.9)	0.91	106 (77.9)
None	26 (22.2)	4 (21.1)		30 (22.1)
Without clavulinate	49 (41.9)	5 (26.3)		54 (39.7)
Whit clavulinate	68 (58.1)	14 (73.7)		82 (60.3)
Steroids	12 (10.3)	1 (5.3)	0.49	13 (9.56)
Hydroxy chloroquine	47 (40.1)	6 (31.6)	0.48	53 (39.0)
No Intensive care no death	99 (84.6)	17 (89.5)	0.23	116 (85.3)
Transfer intensive care unit	18 (15.4)	2 (10.5)	0.58	20 (14.7%)
Death (4 in intensive care unit)	15 (12.8)	1(5.3)	0.34	16 (11.8)

medRxiv preprint doi: https://doi.org/10.1101/2020.09.01.20186213; this version posted September 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.


All rights reserved. No reuse allowed without permission.


485 Figures legends


486


502


- 487 Fig1. Decrease of apolipoprotein-A1 value in the first 30 weeks of 2020.
- 488 1A Global decrease of apolipoprotein-A1 among the sera of patients with risk of liver
- 489 fibrosis in the first 30 weeks of 2020 in USA and France compared to the two previous
- 490 **years** (P<0.001).
- 491 **1B Quantitative decrease of apolipoprotein-A1 by cohort.** Apolipoprotein-A1 decreased
- 492 (P<0.001) in the three cohorts, starting early in January 2020 (red line with 95% confidence
- interval) in the US cohort (lower panel).
- 494 **1C Proportion of serum with low apolipoprotein-A1 by cohorts.** Low apolipoprotein-A1
- was defined as below 1.25 g/L. Details in supplementaryFile2.
- 496 **1D Decrease of apolipoprotein-A1 by gender and age in US cohort.** The same significant
- kinetics were observed, P<0.001 between 2020 and previous years.
- 498 1E Number of confirmed Covid-19 cases per day and proportion of low (<1.25g/L)
- apolipoprotein-A1 in the US cohort during the first 30 weeks of 2020.
- The red graph is the number of confirmed cases per day in logarithmic scale. The black line is
- the daily mean proportion of low apolipoprotein-A1 (<1.25g/L; blue line;95%CI in grey).
- 503 Fig 2. Performances of apolipoprotein-A1 and haptoglobin for the diagnostic and
- prognostic of Covid-19 patients. Details in supplementaryFile2.
- Fig2A. Apolipoprotein-A1 median with IQR between the 6 populations
- Fig2B. Haptoglobin CPAM: general population ASH: severe acute alcoholic hepatitis, DILI:
- drug induced liver disease, RHE: rheumatologic disease, BD: blood donors.
- 508 Fig2C. AUROCs of each FibroTest components.
- 509 Fig2D. Survival without transfer to intensive care unit (ICU).
- The 71 patients with apolipoprotein-A1 value ≥ 0.84 g/L, the median value at inclusion, had
- a significant higher survival without ICU (93.0%;87.0-98.9) than the 65 patients with lower
- 512 value (75.8%;65.1-86.5;P=0.02).




















Click here to access/download

Supporting Information - Compressed/ZIP File Archive

Supplementary material V22 TP.docx.zip